| Filed On | Filing |
|---|---|
| 27 Oct 2026 |
Form 4: Sealbond Ltd, Director and 2 others
Received 4,098,360 shares as a grant or award ($5M) |
| 27 Oct 2026 | SCHEDULE 13D/A |
| 21 Oct 2026 | SCHEDULE 13D/A |
| 19 Oct 2026 |
8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +1 more
THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of October 19, 2026, is entered into by and among Dogwood Therapeutics, Inc., a Delaware corporation (the “Company”), and the undersigned investor hereto (the “Investor”). C... |
| 14 Aug 2026 | SCHEDULE 13G/A |
| 14 Aug 2026 | 10-Q |
| 13 Aug 2026 | 8-K: Results of Operations and Financial Condition |
| 17 Jun 2026 |
Form 4: De La Rosa Abel, Director
Granted 16,800 Stock Option (right to buy) |
| 17 Jun 2026 |
Form 4: Thomas John C, Director
Granted 16,800 Stock Option (right to buy) |
| 17 Jun 2026 |
Form 4: Whitley Richard James, Director
Granted 16,800 Stock Option (right to buy) |
| 17 Jun 2026 |
Form 4: Keefer David R, Director
Granted 16,800 Stock Option (right to buy) |
| 17 Jun 2026 | 8-K: Amendments to Articles/Bylaws; Change in Fiscal Year; Submission of Matters to a Vote of Security Holders |
| 15 May 2026 | SCHEDULE 13G |
| 15 May 2026 | 10-Q |
| 14 May 2026 | 8-K: Results of Operations and Financial Condition |
| 27 Apr 2026 | ARS |
| 27 Apr 2026 |
Proxy statement: annual meeting on June 16, 2026
CEO pay $3.3M, up 280% · say-on-pay vote |
| 17 Apr 2026 | PRE 14A |
| 26 Mar 2026 | 8-K: Regulation FD Disclosure |
| 18 Mar 2026 | 10-K |
Loading...
